[1]Compston J E, McClung M R, Leslie W D. Osteoporosis[J]. Lancet, 2019, 393(10169): 364-376.
[2]中华医学会骨质疏松和骨矿盐疾病分会. 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(4): 317-318.
[3]王泽铖, 阮祥燕, 杨瑜, 等. 医源性早发性卵巢功能不全性激素水平的变化及对糖代谢的影响[J]. 首都医科大学学报, 2024, 45(4): 583-588.
[4]中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志, 2023, 58(1): 4-21.
[5]Shieh A, Ruppert K M, Greendale G A, et al. Associations of age at menopause with postmenopausal bone mineral density and fracture risk in women[J]. J Clin Endocrinol Metab, 2022, 107(2): e561-e569.
[6]Anon. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group[J]. World Health Organ Tech Rep Ser, 1994, 843: 1-129.
[7]Gallagher J C. Effect of early menopause on bone mineral density and fractures[J]. Menopause. 2007,14(3 Pt 2):567-571.
[8]Mäkitie O, Zillikens M C. Early-onset osteoporosis[J]. Calcif Tissue Int, 2022, 110(5): 546-561.
[9]黄国秀, 闭应洲, 潘永华, 等. 中老年女性绝经前后骨丢失率变化趋势及与绝经后骨密度的影响因素分析[J]. 广西医学, 2019, 41(1): 52-55.
[10]中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[11]Tareck R, Stéphanie L. Mechanisms in endocrinology: bone marrow adiposity and bone, a bad romance?[J]. Eur J Endocrinol, 2018, 179(4): 165-182.
[12]Sun L, Peng Y Z, Sharrow A C, et al. FSH directly regulates bone mass[J]. Cell, 2006, 125(2): 247-260.
[13]Wang J, Zhang W W, Yu C X, et al. Follicle-Stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation[J]. PLoS One, 2015, 10(8): e0134986.
[14]Iqbal J, Sun L, Kumar T R, et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation[J]. Proc Natl Acad Sci U S A, 2006, 103(40): 14925-14930.
[15]Zhu L L, Blair H, Cao J, et al. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis[J]. Proc Natl Acad Sci U S A, 2012, 109(36): 14574-14579.
[16]Randolph J F, Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition[J]. J Clin Endocrinol Metab, 2006, 91(8): 3034-3040.
[17]Głogowska-Szelᶏg J. Assessment of the relationship between BMD and body mass index BMI in women with postmenopausal osteoporosis[J]. Wiad Lek, 2018, 71(9): 1714-1718.
[18]Tang Z H, Xiao P, Lei S F, et al. A bivariate whole-genome linkage scan suggests several shared genomic regions for obesity and osteoporosis[J]. J Clin Endocrinol Metab, 2007, 92(7): 2751-2757.
[19]Younesi Asl L, Kashanian M, Najmi Z, et al. Risk factors of osteoporosis and osteopenia in postmenopausal women based on the L2-L4 BMD T score of the lumbar spine: a study in Iran[J]. Gynecol Endocrinol, 2023, 39(1): 2205959.
[20]Hammoud E, Toumi H, Jacob C, et al. Does the severity of obesity influence bone mineral density values in premenopausal women?[J]. J Clin Densitom, 2021, 24(2): 225-232.
[21]Li Y. Association between obesity and bone mineral density in middle-aged adults[J]. J Orthop Surg Res, 2022, 17(1): 268.
[22]Chen B, Liu G W, Wang Y K, et al. The influence of body fat content and distribution on bone mass in healthy Chinese adults[J]. Front Med (Lausanne), 2024, 11: 1403971.
[23]Tang Z H, Xiao P, Lei, S F, et al. A bivariate whole-genome linkage scan suggests several shared genomic regions for obesity and osteoporosis[J]. J Clin Endocrinol Metab,2007,92(7):2751-2757.
[24]Kim S H, Yi S W, Yi J J, et al. Association between body mass index and the risk of hip fracture by sex and age: a prospective cohort study[J]. J Bone Miner Res, 2018, 33(9): 1603-1611.
[25]Fan Z H, Li X Y, Zhang X D, et al. Comparison of OSTA, FRAX and BMI for predicting postmenopausal osteoporosis in a Han population in Beijing: a cross sectional study[J]. Clin Interv Aging, 2020, 15: 1171-1180.
|